The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results JL Mahon, JM Sosenko, L Rafkin‐Mervis, H Krause‐Steinrauf, JM Lachin, ... Pediatric diabetes 10 (2), 97-104, 2009 | 206 | 2009 |
Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial–Type 1 JM Sosenko, JP Palmer, CJ Greenbaum, J Mahon, C Cowie, JP Krischer, ... Diabetes care 29 (3), 643-649, 2006 | 188 | 2006 |
A randomized study comparing a patient-directed hypertension management strategy with usual office-based care KB Zarnke, BG Feagan, JL Mahon, RD Feldman American journal of hypertension 10 (1), 58-67, 1997 | 186 | 1997 |
The Ontario trial of active compression-decompression cardiopulmonary resuscitation for in-hospital and prehospital cardiac arrest IG Stiell, PC Hébert, GA Wells, A Laupacis, K Vandemheen, JF Dreyer, ... Jama 275 (18), 1417-1423, 1996 | 181 | 1996 |
Determination of the clinical importance of study results: A review M Man-Son-Hing, A Laupacis, K O’Rourke, FJ Molnar, J Mahon, ... Journal of general internal medicine 17, 469-476, 2002 | 180 | 2002 |
Health-related quality of life and mobility of patients awaiting elective total hip arthroplasty: a prospective study JL Mahon, RB Bourne, CH Rorabeck, DH Feeny, L Stitt, ... Cmaj 167 (10), 1115-1121, 2002 | 176 | 2002 |
Effect of hydrolyzed infant formula vs conventional formula on risk of type 1 diabetes: the TRIGR randomized clinical trial M Knip, HK Åkerblom, E Al Taji, D Becker, J Bruining, L Castano, T Danne, ... Jama 319 (1), 38-48, 2018 | 157 | 2018 |
N-of-1 (single-patient) trials for statin-related myalgia TR Joy, A Monjed, GY Zou, RA Hegele, CG McDonald, JL Mahon Annals of internal medicine 160 (5), 301-310, 2014 | 154 | 2014 |
The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients JM Sosenko, JS Skyler, JP Palmer, JP Krischer, L Yu, J Mahon, CA Beam, ... Diabetes care 36 (9), 2615-2620, 2013 | 138 | 2013 |
A type 1 diabetes genetic risk score predicts progression of islet autoimmunity and development of type 1 diabetes in individuals at risk MJ Redondo, S Geyer, AK Steck, S Sharp, JM Wentworth, MN Weedon, ... Diabetes care 41 (9), 1887-1894, 2018 | 137 | 2018 |
Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes MJ Haller, DA Schatz, JS Skyler, JP Krischer, BN Bundy, JL Miller, ... Diabetes care 41 (9), 1917-1925, 2018 | 135 | 2018 |
Natural course of remission in IDDM during 1st yr after diagnosis S Martin, B Pawlowski, B Greulich, AG Ziegler, T Mandrup-Poulsen, ... Diabetes Care 15 (1), 66-74, 1992 | 134 | 1992 |
Randomised study of n of 1 trials versus standard practice J Mahon, A Laupacis, A Donner, T Wood Bmj 312 (7038), 1069-1074, 1996 | 130 | 1996 |
A risk score for type 1 diabetes derived from autoantibody-positive participants in the Diabetes Prevention Trial–Type 1 JM Sosenko, JP Krischer, JP Palmer, J Mahon, C Cowie, CJ Greenbaum, ... Diabetes care 31 (3), 528-533, 2008 | 126 | 2008 |
Theophylline for irreversible chronic airflow limitation: a randomized study comparing n of 1 trials to standard practice JL Mahon, A Laupacis, RV Hodder, DA Mc Kim, NAM Paterson, TE Wood, ... Chest 115 (1), 38-48, 1999 | 124 | 1999 |
Insulin resistance and progression to type 1 diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT) PJ Bingley, JL Mahon, EAM Gale, ... Diabetes Care 31 (1), 146-150, 2008 | 122 | 2008 |
The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: a placebo-controlled trial N Muirhead, BF Feagan, J Mahon, RZ Lewanczuk, NW Rodger, F Botteri, ... Current therapeutic research 60 (12), 650-660, 1999 | 117 | 1999 |
Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies L Yu, DC Boulware, CA Beam, JC Hutton, JM Wenzlau, CJ Greenbaum, ... Diabetes care 35 (6), 1213-1218, 2012 | 102 | 2012 |
Surveying physicians to determine the minimal important difference: implications for sample-size calculation C Van Walraven, JL Mahon, D Moher, C Bohm, A Laupacis Journal of clinical epidemiology 52 (8), 717-723, 1999 | 94 | 1999 |
Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in Diabetes Prevention Trial–Type 1 participants JM Sosenko, JS Skyler, CA Beam, JP Krischer, CJ Greenbaum, J Mahon, ... Diabetes 62 (12), 4179-4183, 2013 | 84 | 2013 |